Aug 2026· Journal of Experimental Medicine· Vol 223· 0 citations· 56 references
Medicine
TL;DR
CD1d targeting reshapes tumor immune infiltrates, suppresses tumor growth, and enhances immunotherapy efficacy, suggesting an actionable pathway for therapeutic intervention.
Abstract
Evans et al. identify CD1d as a key regulator of myeloid cell diversity in breast cancer. CD1d targeting reshapes tumor immune infiltrates, suppresses tumor growth, and enhances immunotherapy efficacy, suggesting an actionable pathway for therapeutic intervention.
This study provides evidence for a key role of TNFR1, as expressed by malignant cells, in orchestrating a pro-tumor immunosuppressive environment through secondary inflammatory mediators. Results highlight the relevance of interfering TNFα/TNFR1 in cancer immunotherapy.
Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera et al.· Journal of Experimental Medi...· 0 citations
In this issue of Cell, Lei et al. reveal a reciprocal circuit in which cuproptotic tumor cells promote dendritic cell activation and CD8+ T cell priming, whereas T cell-derived IFN-γ sensitizes tumor cells to FDX1-dependent cuproptosis. This self-reinforcing interaction provides a mechanistic rationale for combining cu...
In Cell Press Blue, Carvalho et al. identify spatially organized tumor-macrophage niches, EMT-like CD44high cancer cells paired with SPP1/PARP14high macrophages, that drive chemoresistance in bladder cancer. PARP14 inhibition can flip this protective niche into an inflammatory, cisplatin-sensitizing state.
Yuzhao Wang, Zibin Chen, Zhuo-Wei Liu et al.· Cancer Cell· 0 citations
The underlying mechanism of tumor microenvironment-induced dysfunction of conventional type 1 dendritic cells (cDC1) remains unclear. Zhang et al. identify transforming growth factor β-driven coactivator-associated arginine methyltransferase 1 (CARM1) as an epigenetic inhibitor of cDC1 cross-presentation. CARM1 is a ce...
Congliang Chen, Xue-Tao Cao· Trends in immunology· 0 citations
The objective response rate of immune checkpoint inhibitors in patients with gastric cancer is limited. Targeting specific subtypes of macrophages holds promise for expanding the potential population sensitive to immune checkpoint inhibitors. This study aims to evaluate the key role of TREM1+tumor‐associated macrophage...